Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320717 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19733022 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL16553003 | 1.00 | MEN1 (0.33) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19732982 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL19732980 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL16553124 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL15319501 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL29593122 | 0.90 | PKM (0.34) | MEN1KMT2AMETF13A1TGM2 | |
| SCHEMBL16552841 | 0.90 | BCL2 (0.32) | MEN1KMT2AMETHSD11B1 | |
| SCHEMBL19733014 | 0.90 | BCL2 (0.32) | MEN1KMT2AMETHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |